Sight Sciences Inc. Common Stock Q3 2025 Earnings Recap

SGHT Q3 2025 November 7, 2025

Get alerts when SGHT reports next quarter

Sight Sciences delivered a robust Q3 2025 with revenues of $19.9 million, driven by strong adoption of its interventional glaucoma technologies and exciting advancements in its dry eye treatment segment.

Earnings Per Share Beat

$-0.16 vs $-0.26 est.

+38.5% surprise

Revenue Miss

19906000 vs 20353540 est.

-2.2% surprise

Market Reaction

1-Day +16.4%

5-Day +54.4%

30-Day +66.0%

See SGHT alongside your other holdings

Add to your portfolio — free

Key Takeaways

Raised full-year 2025 revenue guidance to $76 million to $78 million, reflecting positive momentum.
Achieved key reimbursements in the TearCare segment with new fee schedules in place for over 10 million Medicare-covered lives.
Experienced sequential growth in Surgical Glaucoma revenue, indicating effective operational execution and market demand.
Targeted commercialization efforts underway for TearCare, with a focus on expanding market access and customer advocacy among 6,500 potential adopters.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit SGHT on AllInvestView.

Previous Q2 2025